5.46 NCRN CLL207 Study of Alemtuzumab Consolidation in Chronic Lymphocytic Leukaemia: Response Assessment Follow-up and Pharmacokinetic studies (on Behalf of the NCRI CLL Trials Sub-Group)
暂无分享，去创建一个
W. Gregory | C. Fegan | G. Follows | C. Dearden | Dena R. Cohen | D. Milligan | A. Rawstron | Anne Critchley | A. Varghese | P. Hillmen | C. Pocock | H. McCarthy | E. Skinner | Alex Smith